Next Article in Journal
Combination of Tipifarnib and Sunitinib Overcomes Renal Cell Carcinoma Resistance to Tyrosine Kinase Inhibitors via Tumor-Derived Exosome and T Cell Modulation
Next Article in Special Issue
PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities
Previous Article in Journal
Role of Brachytherapy in the Postoperative Management of Endometrial Cancer: Decision-Making Analysis among Experienced European Radiation Oncologists
Previous Article in Special Issue
PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword
 
 
Review

Article Versions Notes

Cancers 2022, 14(4), 907; https://doi.org/10.3390/cancers14040907
Action Date Notes Link
article pdf uploaded. 11 February 2022 18:32 CET Version of Record https://www.mdpi.com/2072-6694/14/4/907/pdf-vor
article xml file uploaded 16 February 2022 12:28 CET Original file -
article xml uploaded. 16 February 2022 12:28 CET Update -
article pdf uploaded. 16 February 2022 12:28 CET Updated version of record https://www.mdpi.com/2072-6694/14/4/907/pdf-vor
article html file updated 16 February 2022 12:30 CET Original file -
article xml file uploaded 21 February 2022 02:21 CET Update -
article xml uploaded. 21 February 2022 02:21 CET Update https://www.mdpi.com/2072-6694/14/4/907/xml
article pdf uploaded. 21 February 2022 02:21 CET Updated version of record https://www.mdpi.com/2072-6694/14/4/907/pdf
article html file updated 21 February 2022 02:23 CET Update -
article html file updated 31 July 2022 15:44 CEST Update https://www.mdpi.com/2072-6694/14/4/907/html
Back to TopTop